When dividing by post-treatment PIVKA-II levels (>40 mAU/mL), the high-tumor-marker group exhibited a non-significant decrease in AFP levels from 10.4 ng/mL to 2.4 ng/mL (p = 0.084), whereas PIVKA-II levels significantly decreased from 42.0 mAU/mL to 27.0 mAU/mL (p = 0.019). The gene discussed is AFP; the disease is neoplasm.